An update of the Gleason grading system - PubMed (original) (raw)
Review
. 2010 Feb;183(2):433-40.
doi: 10.1016/j.juro.2009.10.046. Epub 2009 Dec 14.
Affiliations
- PMID: 20006878
- DOI: 10.1016/j.juro.2009.10.046
Review
An update of the Gleason grading system
Jonathan I Epstein. J Urol. 2010 Feb.
Abstract
Purpose: An update is provided of the Gleason grading system, which has evolved significantly since its initial description.
Materials and methods: A search was performed using the MEDLINE(R) database and referenced lists of relevant studies to obtain articles concerning changes to the Gleason grading system.
Results: Since the introduction of the Gleason grading system more than 40 years ago many aspects of prostate cancer have changed, including prostate specific antigen testing, transrectal ultrasound guided prostate needle biopsy with greater sampling, immunohistochemistry for basal cells that changed the classification of prostate cancer and new prostate cancer variants. The system was updated at a 2005 consensus conference of international experts in urological pathology, under the auspices of the International Society of Urological Pathology. Gleason score 2-4 should rarely if ever be diagnosed on needle biopsy, certain patterns (ie poorly formed glands) originally considered Gleason pattern 3 are now considered Gleason pattern 4 and all cribriform cancer should be graded pattern 4. The grading of variants and subtypes of acinar adenocarcinoma of the prostate, including cancer with vacuoles, foamy gland carcinoma, ductal adenocarcinoma, pseudohyperplastic carcinoma and small cell carcinoma have also been modified. Other recent issues include reporting secondary patterns of lower and higher grades when present to a limited extent, and commenting on tertiary grade patterns which differ depending on whether the specimen is from needle biopsy or radical prostatectomy. Whereas there is little debate on the definition of tertiary pattern on needle biopsy, this issue is controversial in radical prostatectomy specimens. Although tertiary Gleason patterns are typically added to pathology reports, they are routinely omitted in practice since there is no simple way to incorporate them in predictive nomograms/tables, research studies and patient counseling. Thus, a modified radical prostatectomy Gleason scoring system was recently proposed to incorporate tertiary Gleason patterns in an intuitive fashion. For needle biopsy with different cores showing different grades, the current recommendation is to report the grades of each core separately, whereby the highest grade tumor is selected as the grade of the entire case to determine treatment, regardless of the percent involvement. After the 2005 consensus conference several studies confirmed the superiority of the modified Gleason system as well as its impact on urological practice.
Conclusions: It is remarkable that nearly 40 years after its inception the Gleason grading system remains one of the most powerful prognostic factors for prostate cancer. This system has remained timely because of gradual adaptations by urological pathologists to accommodate the changing practice of medicine.
Copyright 2010 American Urological Association. Published by Elsevier Inc. All rights reserved.
Similar articles
- The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee. Epstein JI, et al. Am J Surg Pathol. 2016 Feb;40(2):244-52. doi: 10.1097/PAS.0000000000000530. Am J Surg Pathol. 2016. PMID: 26492179 Review. - Usual and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in needle biopsy tissue.
Gottipati S, Warncke J, Vollmer R, Humphrey PA. Gottipati S, et al. Am J Surg Pathol. 2012 Jun;36(6):900-7. doi: 10.1097/PAS.0b013e3182495dee. Am J Surg Pathol. 2012. PMID: 22367295 - Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists.
Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. Epstein JI, et al. Adv Anat Pathol. 2006 Jan;13(1):57-9. doi: 10.1097/01.pap.0000202017.78917.18. Adv Anat Pathol. 2006. PMID: 16462155 - Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation.
Srigley JR, Delahunt B, Samaratunga H, Billis A, Cheng L, Clouston D, Evans A, Furusato B, Kench J, Leite K, MacLennan G, Moch H, Pan CC, Rioux-Leclercq N, Ro J, Shanks J, Shen S, Tsuzuki T, Varma M, Wheeler T, Yaxley J, Egevad L. Srigley JR, et al. Pathology. 2019 Aug;51(5):463-473. doi: 10.1016/j.pathol.2019.05.001. Epub 2019 Jul 3. Pathology. 2019. PMID: 31279442 Review.
Cited by
- Role of Systematic Biopsy in the Era of Targeted Biopsy: A Review.
Malewski W, Milecki T, Tayara O, Poletajew S, Kryst P, Tokarczyk A, Nyk Ł. Malewski W, et al. Curr Oncol. 2024 Sep 3;31(9):5171-5194. doi: 10.3390/curroncol31090383. Curr Oncol. 2024. PMID: 39330011 Free PMC article. Review. - The survival outcomes of localized low-risk prostate cancer, a population-based study using NCDB.
Mao S, Samiei A, Yin Y, Wegner RE, Sanguino A, Lyne J, Miller R, Cohen J. Mao S, et al. Cancer Med. 2024 Aug;13(15):e70060. doi: 10.1002/cam4.70060. Cancer Med. 2024. PMID: 39119863 Free PMC article. - Risk of Cancer-related Death for Men with Biopsy Grade Group 1 Prostate Cancer and High-risk Features: A European Multi-institutional Study.
Milonas D, Giesen A, Muilwijk T, Soenens C, Devos G, Venclovas Z, Briganti A, Gontero P, Karnes RJ, Chlosta P, Claessens F, De Meerleer G, Everaerts W, Graefen M, Marchioro G, Sanchez-Salas R, Tombal B, Van Der Poel H, Van Poppel H, Spahn M, Joniau S; European Multicenter Prostate Cancer Clinical and Translational (EMPaCT) Research Group. Milonas D, et al. Eur Urol Open Sci. 2024 Jun 26;66:33-37. doi: 10.1016/j.euros.2024.06.001. eCollection 2024 Aug. Eur Urol Open Sci. 2024. PMID: 39040619 Free PMC article. - MRI-based virtual pathology of the prostate.
Chatterjee A, Dwivedi DK. Chatterjee A, et al. MAGMA. 2024 Aug;37(4):709-720. doi: 10.1007/s10334-024-01163-w. Epub 2024 Jun 10. MAGMA. 2024. PMID: 38856839 Review. - Development and validation of a nomogram to predict cancer-specific survival in nonsurgically treated elderly patients with prostate cancer.
Zhang Z, Cai Q, Wang J, Yao Z, Ji F, Hang Y, Ma J, Jiang H, Yan B, Zhanghuang C. Zhang Z, et al. Sci Rep. 2023 Oct 18;13(1):17719. doi: 10.1038/s41598-023-44911-z. Sci Rep. 2023. PMID: 37853026 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical